Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medtronic has been engaged in a digital transformation. One part of that journey has been work to create a digital twin of their end-to-end supply chain.

Medtronic’s Digital Twin Supports Their Ability To Respond In The Pandemic

Medical device company Medtronic Plc MDT, -0.07% and Foxconn 2354, +1.28% 601138, +1.05% unit Foxconn Industrial Internet, said Thursday they have received the regulatory approval needed to start making ventilators in the U.S.

Medtronic and Foxconn get regulatory nod to start making PB560 ventilators during pandemic

DUBLIN and MOUNT PLEASANT, Wis., June  18, 2020  (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) and Foxconn Industrial Internet, a business group within Foxconn Technology Group (Foxconn), announced today that Foxconn has successfully completed Medtronic’s regulatory and quality requirements necessary to begin manufacturing Medtronic Puritan Bennett™ 560 (PB560) ventilators for Medtronic in the United States. Medtronic and Foxconn are currently ramping up plans to produce 10,000 PB560 ventilators over the next year at Foxconn’s Wisconn Valley Science and Technology Park in Mount Pleasant, Wis. The ventilators will be marketed and sold by Medtronic.

Medtronic and Foxconn Partner to Increase Ventilator Production

With the approval of Medtronic's (MDT) Micra AV, more pacemaker patients will be eligible for a new treatment option.

Medtronic Gets CE Mark for Micra AV Pacer to Treat AV Block

Medtronic Self-Expanding Venous Stent Demonstrates Favorable Outcomes in Patients with Venous Outflow Obstruction

ABRE Study Meets Primary Safety and Effectiveness Endpoints

World’s Smallest Pacemaker Can Now Treat Patients with AV Block, Allowing More Potential Candidates for Leadless Pacing

Medtronic Micra™ AV Receives CE Mark

Boston Scientific

The pandemic has slowed sales for the two medical device companies. Which stock is ready to rise when medical procedures return?

Which Stock Will Bounce Back Best: Medtronic or Boston Scientific?

DUBLIN, June  13, 2020  (GLOBE NEWSWIRE) --   Medtronic plc  (NYSE:MDT), the global leader in medical technology, today announced data on its extended wear infusion set presented at the virtual 80th Scientific Sessions of the American Diabetes Association (ADA). Infusion sets allow people on insulin pump therapy to deliver insulin under the skin to maintain healthy blood glucose levels. Current generation infusion sets must be changed every two to three days. The research revealed that Medtronic Extended infusion sets last twice as long as standard infusion sets with study results suggesting they could provide safe and comfortable wear for patients using Medtronic insulin pumps. It is the only infusion set in the industry with the ability to be used for up to 7 days and adds to the portfolio of technology offerings from Medtronic which aim to reduce burden and enhance user experience. The Medtronic Extended infusion set has received CE Mark, and a U.S. pivotal trial to study the safety and effectiveness is currently underway.

Medtronic Shares Study Results on First of Its Kind Extended Wear Infusion Set from American Diabetes Association Conference

Investment with Blackstone Life Sciences Expected to Accelerate Medtronic Diabetes Pump and CGM Technology Pipeline

Medtronic Announces a $337 Million Product Investment from Blackstone Life Sciences to Expand Development of Future Diabetes Technologies

Data from Two Key Clinical Trials of the Next-Generation Medtronic Automated Insulin Pump Demonstrates Positive Results for Patients with Type 1 Diabetes

Medtronic Presents U.S. Pivotal Trial Data for MiniMed™ 780G Advanced Hybrid Closed Loop System with Automated Correction Bolus Feature

Medtronic's (MDT) CE Marked advanced hybrid closed loop system, MiniMed 780G, is aimed at enhancing management of type 1 diabetes.

Medtronic's CE Marked MiniMed 780G to Aid Diabetes Management

Next Generation Closed Loop Insulin Pump System Features   Auto-Correction Algorithm and Bluetooth Connectivity

Medtronic Secures CE Mark for MiniMed™ 780G Advanced Hybrid Closed Loop System Designed to Further Simplify Type 1 Diabetes Management

Medtronic to Release New Data on     Advanced Hybrid Closed-Loop Systems and Extended-Wear Infusion Set

Medtronic Announces Scientific Data Presentations at the American Diabetes Association 80th Scientific Sessions

Goldman Sachs

Medtronic PLC (MDT) CEO Geoff Martha Presents at Goldman Sachs 41st Annual Global Healthcare Conference (Transcript)

This is not the first time, Medtronic's (MDT) StealthStation surgical navigation system is facing product recall.

Medtronic's StealthStation Feature Recall Classified Class I

Medtronic's (MDT) gets CE Mark recognition for a shorter DAPT indication for HBR patients with Resolute Onyx DES implantation who are at higher risk of bleeding.

Medtronic Resolute Onyx Gets CE Mark for 1-Month DAPT Therapy

DUBLIN, June  05, 2020  (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received CE (Conformité Européenne) Mark for a one-month dual antiplatelet therapy (DAPT) indication for high bleeding risk (HBR) patients implanted with the Resolute Onyx™ Drug-Eluting Stent (DES). For HBR patients, whose bleeding risk may be increased by taking longer DAPT regimens (a combination of aspirin and anti-clotting medication), this new, first-of-its-kind indication allows physicians to recommend a shorter, one-month regimen of DAPT, following a percutaneous coronary intervention (PCI) with Resolute Onyx. The approval is the first of its kind globally. Resolute Onyx DES is available for use in the United States, as well as in Europe and other countries that recognize the CE Mark. Resolute Onyx DES is not currently indicated for HBR patients with one-month DAPT in the United States. Data have been submitted to the FDA with the intent of obtaining a one-month DAPT US Indication for Resolute Onyx DES.

Medtronic Resolute Onyx™ DES Receives First and Only One-Month DAPT Indication for High Bleeding Risk Patients in Europe

Medtronic PLC (MDT) Presents at Jefferies Healthcare Broker Conference Call - (Transcript)

DUBLIN, June  03, 2020  (GLOBE NEWSWIRE) --   Medtronic plc  (NYSE:MDT), the global leader in medical technology, today announced that it will participate in the Goldman Sachs 41st Annual Global Healthcare Conference, held virtually on Tuesday, June 9, 2020.

Medtronic CEO Geoff Martha to Speak at Goldman Sachs Global Healthcare Conference

Medtronic (MDT), in response to the FDA's new guidance due to the coronavirus-led health emergency, has made temporary alterations to its cardiopulmonary product indications for use in ECMO therapy.

Medtronic Alters ECMO Therapy on New FDA Rules for Coronavirus

Medtronic plc (MDT) CEO Geoff Martha presents at Bernstein 36th Annual Strategic Decisions Conference (Transcript)

DUBLIN, May  29, 2020  (GLOBE NEWSWIRE) --    Medtronic plc  (NYSE:MDT), the global leader in medical technology, today announced it will participate in the Jefferies 2020 Global Healthcare Conference, held virtually, on Wednesday, June 3, 2020.

Medtronic EVP & CFO Karen L. Parkhill to Participate in the Jefferies 2020 Global Healthcare Conference

Despite a 17% decline in Medtronic’s stock since the beginning of the year, at the current price of around $95, Medtronic’s stock could see a significant downside, due to the impact of the coronavirus crisis. Medtronic has outperformed the broader markets over the last two years.

Could Medtronic Stock See A 35% Decline From Current Levels?

Medtronic (MDT) expands reach to diabetic patients by introducing the Guardian Connect CGM system's Android version post its FDA clearance.

Medtronic Gets FDA Nod for Guardian CGM's Android Version

Fresenius Medical Care

LeMaitre Vascular

MSA Safety

MSA Safety, Fresnius Medical Care, and LeMaitre Vascular are well-priced stocks on the rise with solid dividends.

News for Medtronic Stock (MDT)